JCB logo
R&D Systems
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents
Published 5 January 2004. doi:10.1083/jcb.200310041
The Rockefeller University Press, 0021-9525 $8.00
JCB, Volume 164, Number 1, 89-96
This Article
Right arrow Full Text
Right arrow PDF (Full Text)
Right arrow PPT slides of all figures
Right arrow Supplemental Material Index
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JCB
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Scott, C. L.
Right arrow Articles by Strasser, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Scott, C. L.
Right arrow Articles by Strasser, A.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Article

 Apaf-1 and caspase-9 do not act as tumor suppressors in myc-induced lymphomagenesis or mouse embryo fibroblast transformation

Clare L. Scott1, Martin Schuler2, Vanessa S. Marsden1, Alex Egle1, Marc Pellegrini1, Dobrila Nesic1, Steve Gerondakis1, Stephen L. Nutt1, Douglas R. Green2 and Andreas Strasser1

1 The Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, 3050, Australia
2 La Jolla Institute for Allergy and Immunology, San Diego, CA 92121

Address correspondence to Andreas Strasser, The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, Victoria, 3050 Australia. Tel.: 61-3-9345-2464 Fax: 61-3-9347-0852. email: strasser{at}wehi.edu.au

Based on experiments with cultured fibroblasts, the apoptosis regulators caspase-9 and Apaf-1 are hypothesized to function as tumor suppressors. To investigate their in vivo role in lymphomagenesis, an IgH enhancer-driven c-myc transgene was crossed onto Apaf-1-/- and caspase-9-/- mice. Due to perinatal lethality, Eµ-myc transgenic Apaf-1-/- or caspase-9-/- fetal liver cells were used to reconstitute lethally irradiated recipient mice. Surprisingly, no differences were seen in rate, incidence, or severity of lymphoma with loss of Apaf-1 or caspase-9, and Apaf-1 was not a critical determinant of anticancer drug sensitivity of c-myc–induced lymphomas. Moreover, loss of Apaf-1 did not promote oncogene-induced transformation of mouse embryo fibroblasts. Thus, Apaf-1 and caspase-9 do not suppress c-myc–induced lymphomagenesis and embryo fibroblast transformation.

Key Words: apoptosis; cancer; Bcl-2; Apaf-1; caspase

M. Schuler and V.S. Marsden contributed equally to this work.

The online version of this article contains supplemental material.

C. Scott's present address is Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724.

M. Schuler's present address is Johannes Gutenberg University Hospital, Mainz, 55101, Germany.

A. Egle's present address is University Hospital Innsbruck, Laboratory for Molecular Cytology, Innsbruck, 6020, Austria.

D. Nesic's present address is Institute of Pathology, University of Bern, Bern, 3010, Switzerland.

Abbreviations used in this paper: C9DN, caspase-9 dominant-negative; MEF, mouse embryo fibroblast; PI, propidium iodide.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents